performance Statement of income Consolidated Financial Statements for Quarter 1 of 2020 Quarter 1 of 2019 Change (Unaudited but reviewed) (Unaudited but reviewed) Increase (Decrease) THB Million % THB Million
1: Overall Financial Performance Unit: million baht Jan-Mar 2019 % Jan-Mar 2020 % Change % YoY Revenue 132.54 100.0% 179.21 100.0% 46.67 35.2% Cost (73.41) (55.4%) (93.71) (52.3%) (20.30) 27.7% Gross
performance Statement of income Consolidated Financial Statements for Quarter 2 of 2020 Quarter 2 of 2019 Change (Unaudited but reviewed) (Unaudited but reviewed) Increase (Decrease) THB Million % THB Million
finance costs due to higher borrowings as a result of previous investments in machinery, subsidiaries, and joint ventures. 2. Overview of Domestic Economy and Ready-to-Drink Fruit Juice Market In Q3/2018
13 November 2019 Subject : Explanation of the operating results for the nine months of the year 2019, change in excess of 20% Attention: Directors and Managers the Stock Exchange of Thailand According
- 2019 Balance by Quarter Change Q2–19 Q1–19 Q2–18 Q2–19 VS Q1–19 Q2–19 VS Q2–18 (Million Baht: MB) (MB) % (MB) % Total Revenue 1,730.1 1,266.8 1,029.9 463.3 36.6 700.2 68.0 Total Operating Expenses
0.00 0.00 Gain from change in a joint venture proportion 9.87 9.87 0.00 0.00 Other income 12.47 (1.28) 15.17 (1.25) Total income 1,168.60 (192.83) 1,181.02 (217.90) The Company wish to explain the main
Operating Fee for trade mark in China and the change on accounting record of the audit fee expense etc. Finance Cost Q1/2019, the Company and its subsidiaries had the financial cost 1.1 MB decreased by 1.8
baht or 0.4 percent compared to non-current assets as of December 31, 2018. The major change was mainly from the decreased of investment property 0.9 million baht. 2 (2) Total Liabilities Company total
results for the six-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech